![]() | ![]() |
Formats:
|
||||||||||
Proliferating cells express mRNAs with shortened 3′ UTRs and fewer microRNA target sites# 1Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA 2Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA 3Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA Address correspondence to: Email: sharppa/at/mit.edu (P.A.S.) or Email: cburge/at/mit.edu (C.B.B.) *these authors contributed equally 4Present address: Department of Cell and Molecular Biology, Karolinska Institutet, 171 77 Stockholm, Sweden Abstract mRNA stability, localization, and translation are largely determined by sequences in the 3′ untranslated region (UTR). Here, we describe a conserved increase in expression of mRNAs terminating at upstream polyadenylation sites (PAS) following activation of primary murine CD4+ T lymphocytes. This program, resulting in shorter 3′ UTRs, is a characteristic of gene expression during immune cell activation and correlates with proliferation across diverse cell types and tissues. Forced expression of full-length 3′ UTRs conferred reduced protein expression. In some cases the reduction in protein expression could be reversed by deletion of predicted microRNA target sites in the variably included region. Our data indicate that gene expression is coordinately regulated such that states of increased proliferation are associated with widespread reductions in the 3′ UTR-based regulatory capacity of mRNAs. The 3′ untranslated region (UTR) of messenger RNA has known functions in the stability, localization, and translation of mRNA (1). These roles are mediated by interactions with regulatory proteins and RNAs, including microRNAs (miRNAs) (2) that act as positive or negative regulators. About half of mammalian genes use alternative cleavage and polyadenylation (APA) to generate multiple mRNA isoforms differing in their 3′ UTRs (3-5). However, the extent to which differential expression of these isoforms is used to regulate mRNA and protein levels in cellular proliferation and differentiation programs is poorly understood. T lymphocyte activation is central to the immune response, and much is known about the associated gene expression and regulation (6). Earlier work demonstrated that APA is regulated in activated T cells (4, 7, 8). In order to provide a better understanding of how APA is used in an active gene expression program, we performed a global analysis of alternative 3′ UTR isoforms during T cell activation. We developed a method for probe-level alternative transcript analysis (PLATA) that uses variation in hybridization of individual oligonucleotide probes on Affymetrix Mouse Exon 1.0 ST microarrays. This platform was used to compare transcripts in resting primary murine T cells expressing CD4 (CD4+) to cells stimulated through the T cell antigen receptor (TCR) for 6 or 48 hours (Figs. S1-S4, Tables S1-S4). APA occurs in both a splicing-independent form (multiple PAS in a terminal exon – here called tandem UTRs) and a splicing-dependent form (mutually exclusive terminal exons - here called 3′ exon switching), diagrammed in Figs. 1A, 1B
In our mouse CD4+ T cell data, TLI changed very little at 6 hours post-stimulation but showed a marked decrease at 48 hours (Fig. 2A
Analysis of a broader panel of human and mouse tissues revealed tissue-biased usage of APA isoforms in agreement with previous studies (3, 5) (Fig. S8B). TLI values from cell lines were consistently lower than for the normal tissue type from which the line was derived (Fig. 2C To assay how different 3′ UTR isoforms influence protein expression, common and full-length 3′ UTRs from several tandem APA genes were fused to a luciferase reporter. To isolate the effects of the UTR on protein expression from efficiency of polyadenylation, a heterologous SV40 PAS was used to terminate both transcripts. Use of the SV40 PAS in the full-length transcript was ensured by deletion of the sequence encoding the proximal PAS (Fig. S9A). In all cases tested, the full-length UTR reporter yielded significantly lower luciferase activity in stimulated primary T cells than the construct containing only the common UTR region (P < 0.01 by two-tailed t-test; Fig. 3A
The extended 3′ UTR region of one tested gene, Hip2, contains conserved seed matches to miR-21 and miR-155, both of which are expressed in activated mouse T cells (9, 10). Overall Hip2 transcript expression was very similar between naïve and activated T lymphocytes; however upon activation relative expression of the extended UTR region decreased while protein levels increased substantially (Fig. 3B, C In agreement with previous studies (11), we found that extended UTR regions contained slightly higher numbers of conserved miRNA seed matches than common regions (Fig. 3E Comparisons of tissue-specific EST libraries have been used to catalog genes with APA and to identify motifs enriched around the PASs of these genes (3, 5, 11, 12). However, to our knowledge a widespread pattern of directed changes in 3′ UTR isoform expression has not been previously described as part of a gene expression program. The observed pattern of decreased relative expression of longer mRNA isoforms could result from a systematic shift in APA or from preferential destabilization of longer mRNA isoforms. The available evidence tends to support regulated APA as being more important, e.g., a stability-based mechanism would predict a significant decrease in mean expression of genes with altered 3′ UTR isoform expression following activation, but no general decrease was observed (Fig. 1F Stimulation of B lymphocytes, T cells, and monocytes results in increased protein expression of the general polyadenylation factor Cstf-64, which plays a role in increased usage of “weaker” upstream PAS in certain 3′ exon switching events in these cell types (7, 13-16). Since Cstf-64 protein expression is also increased as cultured fibroblasts initiate proliferative programs (13), one could imagine that this factor might function as a “master regulator” of PAS selection controlling all of the events that we observe. However, given that Igμ heavy chain PAS selection can be functionally uncoupled from both proliferation and Cstf-64 protein levels in the B cell model (13), and that tandem UTR events respond very differently from 3′ exon switching events in this study, it is likely that additional factors are involved (17-20). The general association of the program of increased relative expression of shorter 3′ UTR isoforms with states of higher proliferation may indicate that UTR-based mRNA regulation plays distinct roles in the regulatory networks of non- or slowly-proliferating cells as compared to actively proliferating cells. It is tempting to speculate that in some cases a shift toward expression of proximal PAS isoforms may be required to evade regulation that would otherwise restrict cell cycle progression. Both of these ideas are consistent with the observation that global downregulation of miRNA expression is observed in human cancers (21) and promotes cellular transformation and tumorigenesis (22). Supporting Onl Click here to view.(2.6M, doc) Acknowledgments We thank members of the Burge and Sharp labs as well as M. Winslow, K. Cante-Barrett, and O. Larsson. This research was supported by the Knut and Alice Wallenberg Foundation (R.S.); the Cancer Research Institute (J.R.N.); the Gina De Felice and Robert M. Lefkowitz (1975) Fund (A.S.); United States Public Health Service grants RO1-GM34277 from the National Institutes of Health, PO1-CA42063 and U19 AI056900 from the National Cancer Institute to PAS and partially by Cancer Center Support (core) grant P30-CA14051 from the National Cancer Institute; and by R01-HG002439 from the NHGRI (C.B.B.). Array data have been deposited in Gene Expression Omnibus (GSE10666). Footnotes #This manuscript has been accepted for publication in Science. This version has not undergone final editing. Please refer to the complete version of record at http://www.sciencemag.org/. Their manuscript may not be reproduced or used in any manner that does not fall within the fair use provisions of the Copyright Act without the prior, written permission of AAAS. References and notes 1. Moore MJ. Science. 2005 Sep 2;309:1514. [PubMed] 2. Bartel DP, Chen CZ. Nat Rev Genet. 2004;5:396–400. [PubMed] 3. Beaudoing E, Gautheret D. Genome Res. 2001;11:1520–6. [PubMed] 4. Edwalds-Gilbert G, Veraldi KL, Milcarek C. Nucleic Acids Res. 1997;25:2547–61. [PubMed] 5. Zhang H, Lee JY, Tian B. Genome Biol. 2005;6:R100. [PubMed] 6. Crabtree GR. Science. 1989 Jan 20;243:355. [PubMed] 7. Chuvpilo S, et al. Immunity. 1999 Feb;10:261. [PubMed] 8. Peattie DA, Hsiao K, Benasutti M, Lippke JA. Gene. 1994;150:251–7. [PubMed] 9. Monticelli S, et al. Genome Biol. 2005;6:R71. [PubMed] 10. Wu H, et al. PLoS ONE. 2007;2:e1020. [PubMed] 11. Legendre M, Ritchie W, Lopez F, Gautheret D. PLoS Comput Biol. 2006;2:e43. [PubMed] 12. Ara T, Lopez F, Ritchie W, Benech P, Gautheret D. BMC Genomics. 2006;7:189. [PubMed] 13. Martincic K, et al. Proc Natl Acad Sci U S A. 1998 Sep 15;95:11095. [PubMed] 14. Shell SA, Hesse C, Morris SM, Jr, Milcarek C. J Biol Chem. 2005 Dec 2;280:39950. [PubMed] 15. Takagaki Y, Seipelt RL, Peterson ML, Manley JL. Cell. 1996 Nov 29;87:941. [PubMed] 16. Takagaki Y, Manley JL. Mol Cell. 1998 Dec;2:761. [PubMed] 17. Brown KM, Gilmartin GM. Mol Cell. 2003 Dec;12:1467. [PubMed] 18. Quesada V, Macknight R, Dean C, Simpson GG. Embo J. 2003 Jun 16;22:3142. [PubMed] 19. Simpson GG, Dijkwel PP, Quesada V, Henderson I, Dean C. Cell. 2003 Jun 13;113:777. [PubMed] 20. Veraldi KL, et al. Mol Cell Biol. 2001 Feb;21:1228. [PubMed] 21. Lu J, et al. Nature. 2005;435:834–8. [PubMed] 22. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Nat Genet. 2007;39:673–7. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||
Science. 2005 Sep 2; 309(5740):1514-8.
[Science. 2005]Nat Rev Genet. 2004 May; 5(5):396-400.
[Nat Rev Genet. 2004]Genome Res. 2001 Sep; 11(9):1520-6.
[Genome Res. 2001]Genome Biol. 2005; 6(12):R100.
[Genome Biol. 2005]Science. 1989 Jan 20; 243(4889):355-61.
[Science. 1989]Nucleic Acids Res. 1997 Jul 1; 25(13):2547-61.
[Nucleic Acids Res. 1997]Immunity. 1999 Feb; 10(2):261-9.
[Immunity. 1999]Gene. 1994 Dec 15; 150(2):251-7.
[Gene. 1994]Nucleic Acids Res. 1997 Jul 1; 25(13):2547-61.
[Nucleic Acids Res. 1997]Genome Res. 2001 Sep; 11(9):1520-6.
[Genome Res. 2001]Genome Biol. 2005; 6(12):R100.
[Genome Biol. 2005]Genome Biol. 2005; 6(8):R71.
[Genome Biol. 2005]PLoS One. 2007 Oct 10; 2(10):e1020.
[PLoS One. 2007]PLoS Comput Biol. 2006 May; 2(5):e43.
[PLoS Comput Biol. 2006]Genome Biol. 2005; 6(8):R71.
[Genome Biol. 2005]Genome Res. 2001 Sep; 11(9):1520-6.
[Genome Res. 2001]Genome Biol. 2005; 6(12):R100.
[Genome Biol. 2005]PLoS Comput Biol. 2006 May; 2(5):e43.
[PLoS Comput Biol. 2006]BMC Genomics. 2006 Jul 26; 7():189.
[BMC Genomics. 2006]Immunity. 1999 Feb; 10(2):261-9.
[Immunity. 1999]Proc Natl Acad Sci U S A. 1998 Sep 15; 95(19):11095-100.
[Proc Natl Acad Sci U S A. 1998]Mol Cell. 1998 Dec; 2(6):761-71.
[Mol Cell. 1998]Mol Cell. 2003 Dec; 12(6):1467-76.
[Mol Cell. 2003]Mol Cell Biol. 2001 Feb; 21(4):1228-38.
[Mol Cell Biol. 2001]Nature. 2005 Jun 9; 435(7043):834-8.
[Nature. 2005]Nat Genet. 2007 May; 39(5):673-7.
[Nat Genet. 2007]